Tags : uniQure

Biotech

uniQure Signs an Exclusive Research and License Agreement with Gen-X

Shots: uniQure has an option to acquire Gen-X to identify novel synthetic promoters to be use in gene therapy products, until the expiry of research collaboration The companies will exclusively work together to develop promoters utilizing SuRE technology for the uniQure’s research pipeline and will explore the further development of AAV vector libraries containing fragments […]Read More

Regulatory

uniQure’s AMT-130 Receives FDA’s Fast Track Designation for Huntington’s Disease

Shots: The FDA’s FT designation follows P-I/II study assessing AMT-130 in patients with Huntington’s disease with an expected initiation in H2’19 FDA grant Fast Track designation to facilitate the development & and expedite the review of drugs to treat serious conditions and fill an unmet medical need AMT-130 is an AVV5 gene therapy one-time administered […]Read More